New hope for blood cancer patients: study tests safer transplant drug combo
NCT ID NCT03246906
First seen May 15, 2026 · Last updated Jun 09, 2026 · Updated 7 times
Summary
This study looked at people with blood cancers receiving a stem cell transplant from an unrelated donor. The goal was to find the best drug combination to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Researchers compared two drug regimens given after a low-dose chemotherapy transplant. The study was stopped early, but the results help guide future treatment choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.